35.35 +0.13 (0.37%)
After hours: 7:00PM EDT
|Bid||35.26 x 900|
|Ask||35.69 x 3000|
|Day's Range||34.24 - 35.27|
|52 Week Range||24.10 - 46.62|
|Beta (5Y Monthly)||0.92|
|PE Ratio (TTM)||11.59|
|Earnings Date||Jul. 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||43.68|
(Bloomberg) -- Boston Scientific Corp. is exploring a sale of its specialty pharmaceutical business focused on treatments for snake venom, which could fetch close to $1 billion, according to people with knowledge of the matter.The Marlborough, Massachusetts-based medical device maker is working with advisers on the potential sale, said the people, who asked to not be identified because the matter isn’t public.No final decision has been made and Boston Scientific could opt to keep the business, they said.A spokesperson for Boston Scientific declined to comment.Boston Scientific’s shares rose 2.3% to close at $35.22 in New York Tuesday, giving the company a market value of about $50.3 billion.It acquired the business in its $4.2 billion takeover of BTG Plc last year. The company is retaining the other parts of BTG’s portfolio, including liver and kidney cancer treatments.News of the potential divestiture was first reported by Dealreporter.(Updates share price in fifth paragraph, adds Mergermarket credit in last paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Shares of medical device makers Becton Dickinson (NYSE: BDX), Boston Scientific (NYSE: BSX), and Medtronic (NYSE: MDT) fell by double-digit percentages in the first six months of 2020, according to data provided by S&P Global Market Intelligence. BD's shares slid 12%, Medtronic's were down 19.2%, and Boston Scientific's tumbled 22.4% during the six-month period, trailing the S&P 500, which was only down a modest 4%. All three companies are diversified manufacturers of hundreds of different pieces of medical equipment and devices, both high- and low-tech.
The pandemic has slowed sales for the two medical device companies. Which stock is ready to rise when medical procedures return?
Boston Scientific's (BSX) EXALT Model D Single-Use Duodenoscope, approved for a TPT payment class by the CMS, will aid Medicare beneficiaries to enjoy the benefits of new and innovative devices.
Boston Scientific (BSX) introduces tool for local measurement and visualization of tissue response to RF ablation treatment in the United States.
A slowdown in medical procedures due to the COVID-19 pandemic caused a decline in first-quarter profits at medical device maker Boston Scientific (NYSE: BSX), but the company still managed a small sales gain, and management made encouraging comments about the future in its earnings call Wednesday. Boston Scientific said on the conference call that its business in the first two months of the year had been consistent with its expectations, which were for sales growth of 10% to 12%. The company's cardiovascular business ended Q1 with a 5.5% sales gain, medical/surgical sales grew 1.1%, and rhythm and neurological sales, which support procedures that are more easily delayed, fell 7.2%.
The Senate approved a new $484 billion stimulus bill on Tuesday, marking another phase of government support and leaving many wondering how the money will be dispersed. Yahoo Finance’s Anjalee Khemlani joins The Final Round panel to break down the latest news about the coronavirus.
Unfortunately for some shareholders, the Boston Scientific (NYSE:BSX) share price has dived 35% in the last thirty...
Today we're going to take a look at the well-established Boston Scientific Corporation (NYSE:BSX). The company's stock...
The yearly results for Boston Scientific Corporation (NYSE:BSX) were released last week, making it a good time to...
Boston Scientific (BSX) is steadily investing in new technologies as well as the global markets, reflecting its uptick in sales across most geographies in Q4.
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
Boston Scientific (BSX) delivered earnings and revenue surprises of 4.55% and -0.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.
Today we are going to look at Boston Scientific Corporation (NYSE:BSX) to see whether it might be an attractive...